{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.60","upperLimit":"43.89","value":"27.5"},{"groupId":"OG001","lowerLimit":"5.43","upperLimit":"28.54","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Composite complete response is defined as complete response (CR), Complete response with incomplete blood count recovery (CRi) or bone marrow complete response (BM-CR) as defined by the International Working Group (IWG) response criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"NUMBER","populationDescription":"Full analysis set: Consisted of all patients who were randomized to one of the two treatment arms","reportingStatus":"POSTED","timeFrame":"48 months","title":"Composite Complete Response (Phase Llb)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}